Navigation Links
Precision Therapeutics Presents Clinical Study Emphasizing the Role of ChemoFx® in Directing Chemotherapy in Gynecological Cancers
Date:6/6/2011

PITTSBURGH, June 6, 2011 /PRNewswire/ -- Dr. Bradley Monk of the Creighton University School of Medicine presented a new gynecologic cancer study at the 2011 American Society of Clinical Oncology (ASCO) Annual Symposium, June 5th in Chicago, Illinois.  The study, titled, Acquired Drug Resistance in Gynecologic Cancer Detected by an In Vitro Assay, begins to answer the question of whether ChemoFx® Drug Response Marker test results taken in the primary setting can be utilized for predicting chemotherapeutic response in the recurrent setting.

To evaluate changes in chemosensitivity, ChemoFx® testing was performed on 30 patient specimens in both the primary and recurrent setting.  Test results were then analyzed to observe the development of resistance to commonly-utilized treatments for recurrent gynecologic cancers.  A significant shift towards resistance was found in the agents carboplatin and paclitaxel, but a significant shift was not observed in other agents studied.  The shift in response for carboplatin and paclitaxel may be attributed to a combination of the two agents being a NCCN® Guideline-recommended first-line therapy for primary ovarian cancer patients.

Though this shift towards resistance should be taken into consideration if a metastatic specimen is available for reanalysis, ChemoFx® results for agents not commonly used as first-line therapies were consistent in both the primary and recurrent setting.  This supports the utility of marker results obtained in the primary setting for assisting in treatment decisions when tissue is not available at the time of recurrence.

"This study suggests that ChemoFx® is able to parallel the clinical portion of ovarian cancer treatment that is associated with predicting which drugs are active in targeting optimal chemotherapy," says Dr. Bradley Monk, Professor in the division of Gynecological Oncology at Creighton University School of Medicine. "Over 1 million cases per year in the U.S. alone are treated with chemotherapy through a 'trial and error' based approach and targeting which agents are most likely to predict response is a major stride in personalizing medicine."

About Precision Therapeutics

Precision Therapeutics, a leading life-science company based in Pittsburgh, Pennsylvania, is dedicated to personalized cancer care.  Precision offers a portfolio of products developed to help guide physicians and patients with difficult clinical decisions throughout the cancer care continuum.

Precision's state of the art bioinformatics combined with the analysis of the live molecular, proteomic and genomic activity of each patient's cancer offer an innovative foundation for further development and commercialization of novel predictive markers for cancer therapy. 

About ChemoFx®

Precision's first commercial test, ChemoFx®, is a proprietary drug response marker which measures an individual's malignant tumor response to a range of standard therapeutic alternatives under consideration by a physician. For more information, please visit www.precisiontherapeutics.com, or www.chemofx.com.


'/>"/>
SOURCE Precision Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. 96-Well Filtration Plate From Varian, Inc. Improves Sensitivity and Precision for Trace Bio-Analysis by LC/MS
2. Applied Precision Announces New Products for Life Sciences Microscopy at the 110th American Society for Microbiology Meeting in San Diego, CA, May 23-26th.
3. Precision Bearing Technologies Featured at Atlantic Design & Manufacturing Show
4. Precision Therapeutics, Inc. Named to Pittsburgh Business Times 2010 Top 100
5. Applied Precisions Mobile Imaging Lab Hits the Road for a Cross-Country Journey
6. Clinical Experts Detail How They Use Varians TrueBeam™ Technology to Improve the Precision and Speed of Cancer Treatments
7. Precision Therapeutics President and CEO Sean McDonald Recognized as a Leading Business Executive and Recipient of 2010 Pacesetters Award
8. Applied Precision Installs a Record Four New DeltaVision OMX Super-Resolution Imaging Systems in Eight Weeks
9. Exempla Saint Joseph Hospital Commences Treating Cancer Patients Using New TrueBeam™ System for High-Precision Image-Guided Radiotherapy and Radiosurgery
10. Abbott Diabetes Care Announces Recall of Certain Lots of Precision Xtra®, Precision Xceed Pro®, MediSense® Optium™, Optium™, OptiumEZ and ReliOn® Ultima Blood Glucose Test Strips in the United States and Puerto Rico
11. Applied Precision Scientific Team to Present 3D-SIM Paper at BiOS in San Francisco
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Eli Lilly and Company ... of its phase 3 EXPEDITION3 trial at the 9 ... As previously disclosed, solanezumab did not meet the primary ... solanezumab initiated in people with mild dementia due to ... submissions for solanezumab for the treatment of mild dementia ...
(Date:12/8/2016)... Mederi Therapeutics Inc . anunciou aprovação regulatória, pela CFDA, e lançamento de ... refluxo gastroesofágico (DRGE). Foto -  http://photos.prnewswire.com/prnh/20161207/446903 ... ... procedure performed and broadcast during the Chinese Congress of Digestive Endoscopy, by Professor ... , , ...
(Date:12/8/2016)... , Dec. 8, 2016  Pennsylvania Physician General ... Drug and Alcohol Programs Gary Tennis ... medications, known as benzodiazepines, developed with the help ... are medications that are frequently prescribed for anxiety ... are used with opioid pain medications, benzodiazepines pose ...
Breaking Medicine Technology:
(Date:12/9/2016)... Woodland Hills, CA (PRWEB) , ... December 09, ... ... center for young adults, celebrated its 10th anniversary with the grand opening of ... Hills, California. The successful event spanned two days, December 2-3, and was attended ...
(Date:12/9/2016)... ... December 09, 2016 , ... Mediaplanet today announces distribution of the latest ... readers to sign up as an organ donor for the 123,000 people in the ... organ donor can save up to 8 saves through organ donation and enhance many ...
(Date:12/9/2016)... ... December 09, 2016 , ... MEDI+SIGN®, a provider ... that a new solution for Emergency Departments (ED) has been added to their ... Emergency Department examination rooms, and with a simplified pallet of information available to ...
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... program through the Pennsylvania Cable Network (PCN) during the summer of 2016. The ... Implementation Grant provided by the United States Department of Health and Human Services ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Florida Hospital Tampa ... Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric medicine. This accreditation identifies ... few hospitals and facilities have earned this distinction. This is the second time ...
Breaking Medicine News(10 mins):